ACC 2026

Part of a multi-speaker ACC session on reimbursement models, governance strategy, and building the business case for AI in cardiology.

Join us for a focused discussion on the newly released ACC/AHA acute Pulmonary Embolism guidelines and what they mean for frontline teams. This session will explore how Viz PE supports guideline-adherent risk stratification, the real-world impact of Viz PE across health systems, and how Viz Assist enables faster, coordinated decision-making in high-risk PE care pathways.

Join us for a moderated Q&A discussion exploring how the Viz.ai Cardio Suite, including HCM and Amyloid solutions, is transforming care delivery across community hospitals and leading Centers of Excellence. Through guided questions, clinical leaders will share real world perspectives on workflow optimization, earlier disease detection, and stronger collaboration across care teams.

Dr. Joshua Lampert will present new data examining patients initially classified as AI-positive but phenotype-negative (AI+, Phenotype−) for hypertrophic cardiomyopathy (HCM).

The study challenges the concept of “false positives,” demonstrating that a meaningful proportion of these patients progress to phenotypic HCM over time — reframing them as “pre-positive” rather than erroneous alerts.